amifostine anhydrous has been researched along with Distorted Hearing in 5 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "High-dose cisplatin combined with etoposide and bleomycin (HDPEB) improves event-free survival (EFS) in advanced pediatric germ-cell tumors (PGCT), but has significant ototoxicity." | 1.33 | Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. ( Billmire, DF; Chang, KW; Davis, MM; Frazier, AL; Giller, R; Lauer, SJ; London, WB; Malogolowkin, M; Marina, N; Olson, TA; Perlman, EJ; Rescorla, F; Womer, RB, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meyer, AK | 1 |
| Young, NM | 1 |
| Marina, N | 1 |
| Chang, KW | 1 |
| Malogolowkin, M | 1 |
| London, WB | 1 |
| Frazier, AL | 1 |
| Womer, RB | 1 |
| Rescorla, F | 1 |
| Billmire, DF | 1 |
| Davis, MM | 1 |
| Perlman, EJ | 1 |
| Giller, R | 1 |
| Lauer, SJ | 1 |
| Olson, TA | 1 |
| Pierson, MG | 1 |
| Møller, AR | 1 |
| Wadler, S | 1 |
| Beitler, JJ | 1 |
| Rubin, JS | 1 |
| Haynes, H | 1 |
| McGill, F | 1 |
| Rozenblit, A | 1 |
| Goldberg, G | 1 |
| Cohen, C | 1 |
| Speyer, J | 1 |
| Runowicz, C | 1 |
| Buzaid, AC | 1 |
| Murren, J | 1 |
| Durivage, HJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| High-Dose Cisplatin, Etoposide and Bleomycin (HD-PEB) Combined With Amifostine in Children With High-Risk Malignant Germ Cell Tumors - A POG Pilot Study[NCT00003811] | Phase 2 | 27 participants (Actual) | Interventional | 2000-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amifostine anhydrous and Distorted Hearing
| Article | Year |
|---|---|
Auditory late effects of chemotherapy.
Topics: Adolescent; Adult; Age Factors; Amifostine; Animals; Antineoplastic Agents; Brain Neoplasms; Child; | 2009 |
2 trials available for amifostine anhydrous and Distorted Hearing
| Article | Year |
|---|---|
Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Combine | 1993 |
High-dose cisplatin plus WR-2721 in a split course in metastatic malignant melanoma. A phase II study.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Drug | 1991 |
2 other studies available for amifostine anhydrous and Distorted Hearing
| Article | Year |
|---|---|
Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
Topics: Adolescent; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Pre | 2005 |
Prophylaxis of kanamycin-induced ototoxicity by a radioprotectant.
Topics: Amifostine; Animals; Guinea Pigs; Hearing; Hearing Disorders; Kanamycin; Organothiophosphorus Compou | 1981 |